HURA Stock Summary and Trading Ideas (Tuhura Biosciences | NASDAQ:HURA)

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Tuhura Biosciences trades on the NASDAQ stock market under the symbol HURA.

As of March 20, 2026, HURA stock price climbed to $1.94 with 1,738,269 million shares trading.

HURA has a beta of 0.67, meaning it tends to be less sensitive to market movements. HURA has a correlation of 0.01 to the broad based SPY ETF.

HURA has a market cap of $109.57 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that HURA belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

HURA has underperformed the market in the last year with a return of -49.6%, while SPY returned +15.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in HURA shares. However, HURA has outperformed the market in the last 3 month and 2 week periods, returning +137.0% and +24.4%, while SPY returned -4.7% and -4.8%, respectively. This indicates HURA has been having a stronger performance recently.

HURA support price is $1.62 and resistance is $1.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HURA shares will trade within this expected range on the day.